Abstract:Background Current staging methods do not accurately predict the risk of disease recurrence and benefit of adjuvant chemotherapy for patients who have had surgery for stage II colon cancer. We postulated that expression patterns of multiple microRNAs (miRNAs) could, if combined into a single model, improve postoperative risk stratification and prediction of chemotherapy benefit for these patients.Methods Using miRNA microarrays, we analysed 40 paired stage II colon cancer tumours and adjacent normal mucosa tissues, and identified 35 miRNAs that were differentially expressed between tumours and normal tissue. Using paraffin-embedded specimens from a further 138 patients with stage II colon cancer, we confirmed differential expression of these miRNAs using qRT-PCR. We then built a six-miRNA-based classifier using the LASSO Cox regression model, based on the association between the expression of every miRNA and the duration of individual patients' disease-free survival. We validated the prognostic and predictive accuracy of this classifier in both the internal testing group of 138 patients, and an external independent group of 460 patients.Findings Using the LASSO model, we built a classifier based on the six miRNAs: miR-21-5p, miR-20a-5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-215. Using this tool, we were able to classify patients between those at high risk of disease progression (high-risk group), and those at low risk of disease progression (low-risk group). Disease-free survival was significantly different between these groups in every set of patients. In the initial training group of patients, 5-year disease-free survival was 89% (95% CI 77.3-94.4) for the low-risk group, and 60% (46.3-71.0) for the high-risk group (hazard ratio [HR] 4.24, 95% CI 2.13-8.47; p<0.0001). In the internal testing set of patients, 5-year disease-free survival was 85% (95% CI 74.3-91.8) for the low-risk group, and 57% (42.8-68.5) for the high-risk group (HR 3.63, 1.86-7.01; p<0.0001), and in the independent validation set of patients, was 85% (79.6-89.0) for the low-risk group and 54% (46.4-61.1) for the high-risk group (HR 3.70, 2.56-5.35; p<0.0001). The six-miRNA-based classifier was an independent prognostic factor for, and had better prognostic value than, clinicopathological risk factors and mismatch repair status. In an ad-hoc analysis, the patients in the high-risk group were found to have a favourable response to adjuvant chemotherapy (HR 1.69, 1.17-2.45; p=0.0054). We developed two nomograms for clinical use that integrated the six-miRNA-based classifier and four clinicopathological risk factors to predict which patients might benefit from adjuvant chemotherapy after surgery for stage II colon cancer.Interpretation Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer, and might be able to predict which patients benefit from adjuvant chemotherapy. It might facilitate patient counselling and individualise management of patients with this disease.

A Circrna Signature Predicts Postoperative Recurrence in Stage II/III Colon Cancer

IDDF2019-ABS-0289 A Circrna Signature Predicts Postoperative Recurrence in Stage II/III Colon Cancer

Fifteen-MiRNA-Based Signature is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

Prognostic and predictive value of a lncRNA signature in patients with stage II colon cancer

A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy

Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer

A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma

Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients

A Novel 9-Gene Signature for the Prediction of Postoperative Recurrence in Stage II/III Colorectal Cancer

A molecular signature for the prediction of recurrence in colorectal cancer

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer

Prognostic and Predictive Value of a Microrna Signature in Stage II Colon Cancer: a Microrna Expression Analysis

Construction and validation of a clinicopathologic signature for predicting the prognosis of stage II and III colorectal cancer

RNA sequencing reveals the expression profiles of circRNA and identifies a four-circRNA signature acts as a prognostic marker in esophageal squamous cell carcinoma

Recurrence risk stratification model for patients with stage I-III colorectal cancer based on clinicopathological and postoperative ctDNA predictors.

Analysis of Circular RNA-Related Competing Endogenous RNA Identifies the Immune-Related Risk Signature for Colorectal Cancer

Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment

CT-Based Radiomics Signature: A Potential Biomarker for Predicting Postoperative Recurrence Risk in Stage II Colorectal Cancer

A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage I-III Bladder Cancer Patients After Surgical Resection.